Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 570.05 Million CNY | -0.37% |
| 2022 | 381.02 Million CNY | -0.57% |
| 2021 | 383.2 Million CNY | 32.95% |
| 2020 | 288.24 Million CNY | 6.22% |
| 2019 | 271.36 Million CNY | 26.75% |
| 2018 | 214.09 Million CNY | 42.35% |
| 2017 | 150.4 Million CNY | 42.62% |
| 2016 | 105.46 Million CNY | 15.01% |
| 2015 | 91.69 Million CNY | 16.1% |
| 2014 | 78.97 Million CNY | 16.6% |
| 2013 | 67.73 Million CNY | 30.77% |
| 2012 | 51.79 Million CNY | 77.25% |
| 2011 | 29.22 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 96.61 Million CNY | 177.56% |
| 2024 Q1 | 77.27 Million CNY | -36.18% |
| 2024 Q2 | 57.96 Million CNY | -24.99% |
| 2023 Q3 | 90.48 Million CNY | 16.13% |
| 2023 FY | 379.63 Million CNY | -0.37% |
| 2023 Q1 | 90.14 Million CNY | -15.22% |
| 2023 Q2 | 77.91 Million CNY | -13.57% |
| 2023 Q4 | 121.08 Million CNY | 33.81% |
| 2022 Q2 | 90.08 Million CNY | 2.27% |
| 2022 Q1 | 88.08 Million CNY | -23.3% |
| 2022 FY | 381.02 Million CNY | -0.57% |
| 2022 Q4 | 106.32 Million CNY | 10.15% |
| 2022 Q3 | 96.53 Million CNY | 7.16% |
| 2021 Q2 | 91.53 Million CNY | 16.58% |
| 2021 Q3 | 98.32 Million CNY | 7.43% |
| 2021 Q1 | 78.51 Million CNY | -3.69% |
| 2021 FY | 383.2 Million CNY | 32.95% |
| 2021 Q4 | 114.83 Million CNY | 16.79% |
| 2020 Q2 | 71.02 Million CNY | 18.36% |
| 2020 Q1 | 60.01 Million CNY | -25.27% |
| 2020 FY | 288.24 Million CNY | 6.22% |
| 2020 Q4 | 81.52 Million CNY | 7.73% |
| 2020 Q3 | 75.67 Million CNY | 6.55% |
| 2019 Q2 | 70.1 Million CNY | 25.85% |
| 2019 FY | 271.36 Million CNY | 26.75% |
| 2019 Q3 | 65.25 Million CNY | -6.91% |
| 2019 Q4 | 80.3 Million CNY | 23.06% |
| 2019 Q1 | 55.7 Million CNY | -22.45% |
| 2018 Q3 | 54.64 Million CNY | 23.42% |
| 2018 Q2 | 44.27 Million CNY | 2.16% |
| 2018 Q1 | 43.34 Million CNY | -8.82% |
| 2018 FY | 214.09 Million CNY | 42.35% |
| 2018 Q4 | 71.82 Million CNY | 31.43% |
| 2017 Q4 | 47.53 Million CNY | 17.24% |
| 2017 Q3 | 40.54 Million CNY | 29.54% |
| 2017 Q2 | 31.3 Million CNY | 0.9% |
| 2017 Q1 | 31.02 Million CNY | -8.88% |
| 2017 FY | 150.4 Million CNY | 42.62% |
| 2016 Q3 | 21.59 Million CNY | -6.36% |
| 2016 FY | 105.46 Million CNY | 15.01% |
| 2016 Q4 | 34.04 Million CNY | 57.65% |
| 2016 Q2 | 23.06 Million CNY | -13.8% |
| 2016 Q1 | 26.75 Million CNY | 0.85% |
| 2015 Q4 | 26.52 Million CNY | 7.64% |
| 2015 FY | 91.69 Million CNY | 16.1% |
| 2015 Q3 | 24.64 Million CNY | 0.0% |
| 2014 FY | 78.97 Million CNY | 16.6% |
| 2013 FY | 67.73 Million CNY | 30.77% |
| 2012 FY | 51.79 Million CNY | 77.25% |
| 2011 FY | 29.22 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.78 Billion CNY | 68.061% |
| Joinn Laboratories(China)Co.,Ltd. | 505.68 Million CNY | -12.729% |
| WuXi AppTec Co., Ltd. | 4.73 Billion CNY | 87.973% |
| Autobio Diagnostics Co., Ltd. | 1.52 Billion CNY | 62.635% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 2.35 Billion CNY | 75.797% |
| Chemclin Diagnostics Co., Ltd. | 169.33 Million CNY | -236.653% |